

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
12 December 2024 (12.12.2024)



(10) International Publication Number
WO 2024/251196 A1

(51) International Patent Classification:

A61K 47/68 (2017.01) *A61K 39/395* (2006.01)
C07K 16/00 (2006.01) *A61P 35/00* (2006.01)
C07K 16/28 (2006.01) *A61P 31/00* (2006.01)

(21) International Application Number:

PCT/CN2024/097745

(22) International Filing Date:

06 June 2024 (06.06.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2023/098791

07 June 2023 (07.06.2023)

CN

(71) Applicant (for CN only): **WUXI XDC (SHANGHAI) CO., LTD.** [CN/CN]; Room 368, Section 302, 211 Fute North Road, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai 200131 (CN).

(71) Applicant (for all designated States except CN): **WUXI XDC SINGAPORE PRIVATE LIMITED** [SG/SG]; 100 Tras Street #16-01 100 AM, 079027 (SG).

(72) Inventors: **FAN, Qirui**; Room 368, Section 302, 211 Fute North Road, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai 200131 (CN). **ZHANG, Lin**; Room 368, Section 302, 211 Fute North Road, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai 200131 (CN). **WANG, Laisen**; Room 368, Section 302, 211 Fute North Road, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai 200131 (CN).

(74) Agent: **CCPIT PATENT AND TRADEMARK LAW OFFICE**; 10/F, Ocean Plaza, 158 Fuxingmennei Street, Xi-cheng District, Beijing 100031 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,

(54) Title: PROCESS FOR PREPARING ANTIBODY-DRUG CONJUGATES WITH IMPROVED HOMOGENEITY




Fig. 22

(57) Abstract: Provided herein is a bio-conjugation process for preparing a composition of antibody-drug conjugates (ADCs) with improved homogeneity, wherein the antibody-drug conjugates (ADCs) with drug to antibody molar ratio of 2 (D2) are present in a high level in the composition. In the composition of ADCs prepared by the process of the present disclosure, the content of D2 is higher than 64 mol%, and the content of D0+D4+D6+D8 is less than 36 mol%, on the basis of total molar of D0, D2, D4, D6 and D8.

[Continued on next page]

MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))